Conference-Service.com stellt der Öffentlichkeit ein Kalendarium wichtiger Konferenzen, Symposien und sonstiger Tagungen im wissenschaftlich-technischen Bereich zur Verfügung. Obwohl das Verzeichnis mit großer Sorgfalt zusammengestellt und ständig aktualisiert wird, weisen wir auf die Möglichkeit von Fehlern ausdrücklich hin. Bitte vergewissern Sie sich immer beim Veranstalter, bevor Sie über die Teilnahme oder Nichtteilnahme an einer Konferenz entscheiden.
Organisatoren können kostenlos ihre Konferenzankündigungen veröffentlichen.
The NGBT conference is jointly hosted with Centre for the Commercialization of Antibodies and Biologics (CCAB), Toronto, Canada, Tata Institute of Fundamental Research (TIFR Biology Department), Mumbai, India, and Institute of Bioinformatics (IOB), Bengaluru, India. This is the sixth international conference that is hosted by SGRF Conferences, the educational outreach arm of SciGenom Research Foundation (SGRF), along with national institutes in India.
Uniting senior scientists from chemistry and biology, Discovery Informatics & Analytics 2016 offers inspirational keynote speeches, practical case studies offering immediate takeaways, interactive discussion sessions, and maximum opportunity to engage and network with colleagues from Europe and beyond.
The genome editing market represents a rapidly evolving area of pharmaceutical research since the discovery of the CRISPR/Cas systems that have revolutionised biological research. Significant advancements have been made in the fields of improving genome editing tools & technologies, gene delivery systems and utilising genome editing for therapeutic applications. Genomics research is experiencing an increased funding and thanks to the technological advancements the genome editing market is expected to grow rapidly. Experts have also highlighted that the global market for genome editing is expected to reach over $2.0 billion by 2020.
In the past few years, exceptional progress has been made in the application of genetics- and genomics-based technologies in biomedical research. There are currently thousands of DNA variants that are robustly associated with clinically relevant human traits. Although these should provide a rich source of molecular starting points for drug discovery, and a deeper understanding of their role in human physiology, the translation of these data from large-scale projects has been slow to influence the selection and validation of new targets in drug discovery and development programmes.
This meeting will bring together researchers based in academia and industry to focus on the opportunities and challenges for genomics in drug discovery. Epidemiology, molecular biology and computational approaches will be covered with a focus on contributions these methods can offer to the development of new therapies to treat patients. The potential of human cellular assays that can be perturbed genetically (by RNAi or CRISPR) or chemically will also be emphasised.
During the last decade, it has become unequivocally evident that tumor development is not a cell-autonomous process but rather depends on the intricate reciprocal interplay of mutant tumor cells with their local and distant environments. Composition and polarization of cells in the tumor microenvironment depends on genetic as well as environmental factors and is directly influenced by tumor therapy. Indeed, therapies that aim to shape the local immune milieu and consecutive signaling pathways in both stromal and tumor/stem cells address the complex pathophysiology of tumors more adequately and may therefore add substantial benefits for therapy. An absolute pre-requisite for such an endeavor is a comprehensive understanding of the exact molecular basis of the complex signaling networks in the tumor microenvironment that control the plasticity of both stromal and tumor cells, thereby shaping the complex cellular contexture, which ultimately forms a pro- or anti-tumorigenic milieu. Thus, this symposium aims to gather a comprehensive functional understanding of mediator-dependent cellular and molecular events that are responsible for the plasticity of both stromal and tumor/stem cells. It will bring together experts in cancer, stromal and immune cells to synthesize scientific knowledge about the phenomenon of cell plasticity within the tumor microenvironment, to define molecular and cellular pathways mediating plasticity and to propose approaches to interfere with cell plasticity for a new generation of effective therapeutic approaches in cancer and chronic injury. Importantly, it will bring together interdisciplinary groups of scientists or investigators who normally would not have an opportunity to meet (classical cancer biologists, tumor immunobiologists, stem cell experts and scientists working on stromal cells).
The objective of this meeting is to bring together leaders in the field to discuss latest advances in stem cell biology with an emphasis on transcriptional and epigenetic mechanisms of gene regulation in pluripotent and neural stem cells. It will elucidate the roles of transcriptional regulators and chromatin structure in defining stem cell identity. These presentations will be complemented by talks on experimentally induced cell fate changes during reprogramming to pluripotency and transdifferentiation into various cell lineages. We will further discuss efforts to capture distinct stem cell types and states from the preimplantation embryo including naïve human embryonic stem cells. Advances in pluripotent stem cells will be compared and contrasted with recent insights into the biology of neural stem cells, including discussions of their origin, specification and turnover. Lastly, two sessions dedicated to disease modeling and cell therapy, respectively, will highlight ongoing attempts to study and treat diseases using stem cells from the hematopoietic and neural systems. This meeting is being held jointly with
Oh, and over 100 professionals working in academia, drug development, investment, healthcare, data labs, all sharing their expertise to an audience who thought...
Its 3 day event which includes Keynote sessions, featured speakers, students, companies. We encourage delegates to use this conference as a meeting place to assemble their academic interest-groups for global deliberations.
Speakers: Christa Schleper, Gordon Brown, Ian Baldwin, Jon Clardy, Michael Meyer-Herman, Manja Marz, Oliver Kurzai, Sarah O´Connor and Susan Trumbore
European Cancer Genomics research is particularly strong in the Heidelberg area, with three International Cancer Genome Consortium (www.icgc.org) projects being currently pursued with significant participation from Heidelberg institutions, including EMBL. As in our 2015 meeting, a large number of renowned speakers will be invited, with a strong representation of overseas speakers. The atmosphere at the conference will make this an exceptional event with cutting edge science, extensive scientific discussions and ample possibilities for meetings between and after sessions to facilitate in-depth discussions and new collaborations.
Stand vom 23. September 2016